Daily News Podcast

Rivaroxaban beats aspirin for VTE


 

Both low-dose and full-dose rivaroxaban had superior benefit-risk profiles for extended VTE compared with aspirin. Also today, bone biopsy diagnostics for osteomyelitis vary widely, variation in bacterial drug susceptibility are tied to the risk of TB relapse, and CTA cuts MIs in patients with stable chest pain. Subscribe to the MDedge Daily News wherever you get your podcasts.
Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

Psoriasis registry study provides more data on infliximab’s infection risk
MDedge Infectious Disease
Open AAA and peripheral bypass surgery patients among the highest users of post-acute care
MDedge Infectious Disease
Sleepio app tied to reducing insomnia, depression
MDedge Infectious Disease
5 digital HIPAA myths
MDedge Infectious Disease
Screen for cervical cancer based on age, risk
MDedge Infectious Disease
Is it time for PCPs to take over chronic HCV?
MDedge Infectious Disease
Rivaroxaban data abound at ESC 2018
MDedge Infectious Disease
New MI definition for infarction vs injury
MDedge Infectious Disease
Lorcaserin shows cardiovascular safety
MDedge Infectious Disease
Lung function decline linked to cardiovascular risk
MDedge Infectious Disease